• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patient recruitment and retention tactics vary

Patient recruitment and retention tactics vary

February 8, 2016
CenterWatch Staff

Patient recruitment and retention tactics vary as much as the protocols they support. While the primary focus is on the recruitment of individuals into clinical trials, sometimes it’s difficult to keep people in a clinical research study after they have signed up. Understanding why people drop out, when they typically drop out and uncovering the root cause is the basis for many retention strategies. 

One of the main reasons people discontinue participating in clinical trials is simply “because they can.” According to the language in the informed consent form (ICF)—the comprehensive legal and regulatory document that spells out the contractual rights of the study participant—patients can stop participation at any time for any reason. The execution of the ICF is required documentation to initiate screening or participation in any clinical trial. Because of the clarity of the message, many patients actually do. 

How many study participants act on that fundamental right varies from study to study, but according to The Prevention and Treatment of Missing Data in Clinical Trials, patient dropout rates in phase III clinical trials “can often be very substantial,” sometimes more than 30%. This percentage can be more in some studies, especially studies with long durations, multiple blood draws, fasting requirements and invasive procedures. Other reasons people drop are not necessarily study specific. A participant’s motivation may diminish because of inconvenience factors like parking, appointment times and waiting room time. Complex studies with multiple endpoints and inconvenience factors create additional burdens that negatively affect both the study site and study participants. 

cww2005_pulse

Basic retention strategies that historically have been implemented include study-branded appreciation items. Examples range from tote bags and branded water bottles to more sophisticated objects or devices. Unfortunately, many of these items intended to show appreciation to the volunteering patient miss the mark. Objects themselves don’t show value to a participant—it is how they are treated that matters. Imagine extended time in a waiting room, not having a parking spot, encountering busy staff who have little time to engage and then being given an object of minimal value. In this example, the objects may do little to enhance the appreciation felt by the study participant. 

The study site staff’s treatment of the patients themselves may be the most important factor in retaining patients. Sites can create value among participants by proactively cultivating relationships and remaining in close contact with patients through regular, medically-oriented calls to patients and mailing study appointment reminder/thank you cards. Provide sites with a set of subject-focused materials that will recognize the subjects’ efforts and commitment toward the study and make them feel part of a special community helping to advance research for themselves and others like them. Retention items should be carefully selected and focused on building loyalty to the study and will reinforce messages such as the importance of compliance, the value of the subject’s participation to science and the support available at the clinical site.

CISCRIP’s Medical Heroes is a retention program that puts volunteering for a clinical trial into perspective. This entire concept is based on the premise that those participating in clinical trials are heros and deserve to be recognized for their contribution to medical research. The Medical Heroes Campaign shines a light on the importance of the “gift of participation.” Retention programs should remember that most people participate in clinical trials for altruistic reasons. The top two reasons people volunteer for clinical trials, according to CISCRIP, are to advance medicine and to improve the lives of others. Keeping the patients motivation in mind is the first step in developing a retention program that truly values the patient commitment. 

 

Ashley Tointon has more than 18 years of patient recruitment and project management experience supporting clinical trials and the pharmaceutical industry. Currently, she provides recruitment expertise, strategy and leadership as Principal Consultant of Accelerate Clinical Enrollment. Email comments and suggestions to tointon@icloud.com.

This article was reprinted from CWWeekly, a leading clinical research industry newsletter providing expanded analysis on breaking news, study leads, trial results and more. Subscribe »

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing